Wednesday, July 8, 2026

Patent intelligence · US

US 12171758

Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto

granted A61KA61K31/4709A61PA61P25/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 6
Patent details — US 12171758
Jurisdiction
US
Status
granted
Grant date
Dec 24, 2024
Expiration
Dec 19, 2044
Claims
30
CPC classes
A61K, A61K31/4709, A61P, A61P25/06
View on Google Patents ↗

Quick answer

US 12171758 (Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K31/4709, A61P, A61P25/06, A61P25/18, A61P25/24

More from Neumora Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12371414

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Expires Jul 24, 2045

    granted
  2. US 12247037

    1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

    Neumora Therapeutics, Inc. · Expires Mar 6, 2045

    granted
  3. US 12152038

    Vasopressin receptor antagonists and products and methods related thereto

    Neumora Therapeutics, Inc. · Expires Nov 21, 2044

    granted
  4. US 11993580

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. · Expires May 23, 2044

    granted
  5. US 11858943

    Vasopressin receptor antagonists and products and methods related thereto

    Neumora Therapeutics, Inc. · Expires Dec 28, 2043

    granted

Frequently asked questions

What is US patent 12171758?

US 12171758 (Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12171758?

Neumora Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.

When does US 12171758 expire?

Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.